Aptitude Health’s Post

The use of the VEGF inhibitors sorafenib, sunitinib, and pazopanib was associated a 2-fold increase in the risk of aortic aneurysm and aortic dissection in patients with cancer. https://ja.ma/49ITPs0

Earn Free #CME: Join Drs. Porter and Schwartzberg in a deep dive into Trop-2, Antibody-drug conjugates data and treatment plans to improve care for patients with #BreastCancer and #Lung Cancer. https://brnw.ch/21wLb8O

Surveillance screening via digital breast tomosynthesis (DBT) immediately after breast cancer treatment is effective. https://smpl.is/8cjbp

#ColorectalCancerAwarenessMonth Linking ctDNA 🧬 to long-term outcomes and using it to guide treatment decisions. 📌ctDNA detection of MRD is a powerful prognostic and predictive tool in patients with stage II and III colorectal #cancer 📌ctDNA positivity at any MRD testing point was prognostic for inferior disease-free survival 📌ctDNA positivity was predictive of the ­benefit of chemotherapy 💉; ctDNA-positive patients followed with ­observation were significantly more likely to have a recurrence. 📌Sustained ctDNA clearance was associated with superior disease-free survival compared with transient or no clearance. 📌Patients appreciated 🙏the use of ctDNA and the information it produced in guiding their treatment. Read More Here - https://lnkd.in/gsZA8D-J #CancerTreatment #LiquidBiopsy #ctDNA #Therapy #ASCOGIC #4baseCare #TogetherWeBeatCancer Thanks Dr. Pashtoon Kasi for this outstanding share. American Society of Clinical Oncology (ASCO)

NEJM: Ribociclib plus Endocrine Therapy in Early Breast Cancer https://lnkd.in/ejAk697K https://lnkd.in/eKfyUzmp BACKGROUND Ribociclib has been shown to have a significant overall survival benefit in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer. Whether this benefit in advanced breast cancer extends to early breast cancer is unclear. METHODS In this international, open-label, randomized, phase 3 trial, we randomly assigned patients with HR-positive, HER2-negative early breast cancer in a 1:1 ratio to receive ribociclib (at a dose of 400 mg per day for 3 weeks, followed by 1 week off, for 3 years) plus a nonsteroidal aromatase inhibitor (NSAI; letrozole at a dose of 2.5 mg per day or anastrozole at a dose of 1 mg per day for ≥5 years) or an NSAI alone. Premenopausal women and men also received goserelin every 28 days. Eligible patients had anatomical stage II or III breast cancer. Here we report the results of a prespecified interim analysis of invasive disease–free survival, the primary end point; other efficacy and safety results are also reported. Invasive disease–free survival was evaluated with the use of the Kaplan–Meier method. The statistical comparison was made with the use of a stratified log-rank test, with a protocol-specified stopping boundary of a one-sided P-value threshold of 0.0128 for superior efficacy. RESULTS As of the data-cutoff date for this prespecified interim analysis (January 11, 2023), a total of 426 patients had had invasive disease, recurrence, or death. A significant invasive disease–free survival benefit was seen with ribociclib plus an NSAI as compared with an NSAI alone. At 3 years, invasive disease–free survival was 90.4% with ribociclib plus an NSAI and 87.1% with an NSAI alone (hazard ratio for invasive disease, recurrence, or death, 0.75; 95% confidence interval, 0.62 to 0.91; P=0.003). Secondary end points — distant disease–free survival and recurrence-free survival — also favored ribociclib plus an NSAI. The 3-year regimen of ribociclib at a 400-mg starting dose plus an NSAI was not associated with any new safety signals. CONCLUSIONS Ribociclib plus an NSAI significantly improved invasive disease–free survival among patients with HR-positive, HER2-negative stage II or III early breast cancer.

Exploring the promise of #CDK46Inhibitors in treating breast cancer! We're excited to share Dr. Albert Grinshpun's recent article exploring the promise of #CDK46Inhibitors in treating both advanced and early-stage breast cancer! Based on the opinion paper, the following conclusions were drawn: 🎗Increased survival: These targeted therapies paired with endocrine therapy show significant potential in advanced cases. 🎗Reduced recurrence: Early-stage trials suggest promising results in minimizing recurrence risk for specific patients. 🎗Personalized approach: Tumor biology analysis helps tailor treatment for optimal outcomes. Dr. Grinshpun's expertise guides our mission to deliver personalized, cutting-edge care. Read his full article: https://lnkd.in/epxSAajh! #SharettOncologyInstitute #BreastCancer #Research #HopeThroughInnovation

📢 New Article Published! The latest research in the Annals of Surgical Oncology highlights the critical importance of monitoring breast cancer patients for lymphedema for at least three years post-treatment. Early detection using bioimpedance spectroscopy (BIS) can prevent progression to chronic lymphedema, ensuring better patient outcomes. “Breast cancer related lymphedema can develop years after cancer treatment is concluded and can progress from the subclinical stage, where intervention is possible to reverse progression, to chronic lymphedema, where this can become a lifelong condition” says Dr. Steven Chen, co-author of the article and Chief Medical Officer, ImpediMed. Read more about these important findings and their implications for patient care in our latest news release: https://ow.ly/zVa650SCMVx #LymphedemaAwareness #BreastCancerCare #EarlyDetection

Addition of Tucatinib to Breast Cancer Maintenance Therapy Aims to Fill Unmet Need for Patients With Brain Metastases #changingthefaceofbreastcancer #breastcancerinmen #BreastCancerResearch #breastcancertreatment

In Case You Missed It: Key Lymphedema Insights! A recent publication in the Annals of Surgical Oncology underscores a crucial point: monitoring for lymphedema for at least three years post-breast cancer treatment is vital. Early detection with bioimpedance spectroscopy (BIS) is a game-changer in preventing chronic lymphedema and ensuring better patient outcomes. Dr. Steven Chen, ImpediMed’s Chief Medical Officer, explains: “Lymphedema can develop years after treatment and may shift from a reversible stage to a chronic condition.” Don’t miss the full update and its impact on patient care: https://ow.ly/h0jU50TgJsG #LymphedemaAwareness #BreastCancerCare #EarlyDetection

The EMBARK trial sheds light on the complex decision-making involved in treating biochemically recurrent prostate cancer. 📉While enzalutamide shows promise in delaying metastasis, we must carefully consider the impact of early treatment on quality of life and long-term outcomes. ❗️Balancing the benefits of treatment-free survival with the risks of prolonged therapy is key. ❓What are your thoughts on managing BCR with these new insights? OncoDaily OncoAlert European School of Oncology